Singapore markets closed

PFE Oct 2024 38.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.1400+0.1100 (+366.67%)
As of 02:58PM EDT. Market open.
Full screen
Previous close0.0300
Open0.1400
Bid0.0600
Ask0.1200
Strike38.00
Expiry date2024-10-18
Day's range0.1400 - 0.1400
Contract rangeN/A
Volume1
Open interest530
  • Benzinga

    Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

    On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Lyme disease is a bacterial infection that can be spread to humans by infected ticks. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025. "VLA15, the Lyme disease vaccine candidate we are co-developing wit

  • Benzinga

    Pfizer And Roche Advance On Their Weight Loss Drug Journeys

    After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE: LLY) and Novo Nordisk (NYSE: NVO) who are currently dominating the we

  • Barrons.com

    Eli Lilly, Novo Nordisk Stocks Are Dropping. A Rival Had Upbeat Weight-Loss News.

    Roche said that a Phase 1 clinical trial for CT-996, a once-daily oral GLP-1 receptor, showed positive top-line results.